Dutch Fund raises €250M to invest in Late Stage Biotechs

15/06/2016 - 2 minutes

Gilde Healthcare has raised €250M for its 4th fund in an oversubscribed round. The money will go to late-stage MedTech, digital health and therapeutics, which can join a portfolio with some of the European celebrity-Biotechs.

gilde_healthcare_iv_fund_biotechGilde Healthcare is based in Utrecht (Netherlands) and Cambridge (Massachussets), investing in healthcare companies on both sides of the Atlantic.

This VC has now raised €250M for its 4th fund – Gilde Healthcare IV. The round was backed by a mix of international investors, which included well-known Dutch company Philips (technology giant also with MedTech products) and Johnson & Johnson Innovation (US).

For the IV Fund, single investments in each biotech will be between €15M and €25M. The current portfolio includes companies like Agendia (which developed a diagnostic test for breast cancer), Acacia (developing anti-nausea medication) and Symphogen (one of the top biotechs in Copenhagen).

Gilde’s strategy to investing focuses on later stages of Biotech,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: